Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast01
jRCT2031210440Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in breast cancer (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Progression-Free Survival and Overall Survival. Started Jan 2022; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031210440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210440.